The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities
- PMID: 2458130
- DOI: 10.1021/bi00411a029
The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities
Abstract
S-Protein/vitronectin is a serum glycoprotein that inhibits the lytic activity of the membrane attack complex of complement, i.e., of the complex including the proteins C5b, C6, C7, C8, and C9n. We show that intact S-protein/vitronectin or its cyanogen bromide generated fragments also inhibit the hemolysis mediated by perforin from cytotoxic T-cells at 45 and 11 microM, respectively. The glycosaminoglycan binding site of S-protein/vitronectin is responsible for the inhibition, since a synthetic peptide corresponding to a part of this highly basic domain (amino acid residues 348-360) inhibits complement- as well as perforin-mediated cytolysis. In the case of C9, the synthetic peptide binds to the acidic residues occurring in its N-terminal cysteine-rich domain (residues 101-111). Antibodies raised against this particular segment react 25-fold better with the polymerized form of C9 as compared with its monomeric form, indicating that this site becomes exposed only upon the hydrophilic-amphiphilic transition of C9. Since the cysteine-rich domain of C9 has been shown to be highly conserved in C6, C7, and C8 as well as in perforin, the inhibition of the lytic activities of these molecules by S-protein/vitronectin or by peptides corresponding to its heparin binding site may be explained by a similar mechanism.
Similar articles
-
Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.J Immunol. 1993 Aug 15;151(4):2159-65. J Immunol. 1993. PMID: 8345200
-
Inhibition of the lytic activity of perforin (cytolysin) and of late complement components by proteoglycans.Mol Immunol. 1987 Sep;24(9):907-13. doi: 10.1016/0161-5890(87)90002-2. Mol Immunol. 1987. PMID: 3498887
-
Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.Clin Exp Immunol. 1993 Apr;92(1):114-9. doi: 10.1111/j.1365-2249.1993.tb05956.x. Clin Exp Immunol. 1993. PMID: 7682159 Free PMC article.
-
Transmembrane channel-formation by five complement proteins.Biochem Soc Symp. 1985;50:235-46. Biochem Soc Symp. 1985. PMID: 2428370 Review.
-
Membrane attack by complement.Mol Immunol. 1984 Jul;21(7):589-603. doi: 10.1016/0161-5890(84)90044-0. Mol Immunol. 1984. PMID: 6379417 Review.
Cited by
-
Identification and therapeutic potential of a vitronectin binding region of meningococcal msf.PLoS One. 2015 Mar 31;10(3):e0124133. doi: 10.1371/journal.pone.0124133. eCollection 2015. PLoS One. 2015. PMID: 25826209 Free PMC article.
-
Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid.Proc Natl Acad Sci U S A. 1989 Sep;86(18):7123-7. doi: 10.1073/pnas.86.18.7123. Proc Natl Acad Sci U S A. 1989. PMID: 2780565 Free PMC article.
-
Interaction of heparin with synthetic antithrombin III peptide analogues.Biochem J. 1994 Jul 1;301 ( Pt 1)(Pt 1):121-9. doi: 10.1042/bj3010121. Biochem J. 1994. PMID: 8037658 Free PMC article.
-
Complement inhibition by human vitronectin involves non-heparin binding domains.Clin Exp Immunol. 1995 Jul;101(1):136-41. doi: 10.1111/j.1365-2249.1995.tb02289.x. Clin Exp Immunol. 1995. PMID: 7542572 Free PMC article.
-
Binding of S protein by Neisseria gonorrhoeae and potential role in invasion.J Clin Microbiol. 1991 Jan;29(1):70-5. doi: 10.1128/jcm.29.1.70-75.1991. J Clin Microbiol. 1991. PMID: 1704384 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous